92 activities found

Webcast: Considerations for Pre-operative Therapy to Optimize Care of Women with HER2+ Breast Cancer

Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. This activity features Edibaldo Silva-Lopez, MD, a surgical oncologist from the University of Nebraska Medical Center in Omaha discussing key information that frames much of the current perception about and emerging evidence on this important clinical topic.
0.5 CME

Interactive Case: HER2+ BC Case 1: Potential Role of Neoadjuvant Therapy for a 30 yo Woman with T2 N1 BC

Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. To explore core clinical management challenges in this disease setting, this activity features a panel of 4 clinical experts from the disciplines of surgical oncology, clinical pathology, radiation oncology, and medical oncology using a tumor board format to discuss the case a 30-year-old African-American woman with a small HER2+ tumor in her left breast and a palpable L axillary node.
0.5 CME

Interactive Case: HER2+ BC Case 2: Potential Role of Neoadjuvant Therapy in a 56 yo Woman with T2 N0 ER+/PR+ BC

Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. To explore core clinical management challenges in this disease setting, this activity features a panel of 4 clinical experts from the disciplines of surgical oncology, clinical pathology, radiation oncology, and medical oncology using a tumor board format to discuss the case a 56-year-old woman who is postmenopausal and has a 3 cm breast tumor that is HER2+ and is estrogen receptor positive (ER+) and progesterone receptor positive (PR+).
0.5 CME

Interactive Case: HER2+ BC Case 3: Potential Role of Neoadjuvant Therapy in a 61 yo Woman with T2 N3 HER2+/ER-/PR- BC

Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. To explore core clinical management challenges in this disease setting, this activity features a panel of 4 clinical experts from the disciplines of surgical oncology, clinical pathology, radiation oncology, and medical oncology using a tumor board format to discuss the case a 61-year-old woman who is postmenopausal and has T2 N3 breast cancer that is HER2+ and is estrogen receptor negative (ER-) and progesterone receptor negative (PR-).
0.5 CME

Investigator Insights: New Directions in Targeting Angiogenesis for Metastatic Colorectal Cancer

In the third e-learning activity of this 4-part series, Richard M. Goldberg, MD and Paul Ruff, MD discuss the key clinical study data presented at the 2015 annual meeting of the American Society for Clinical Oncology (ASCO) pertaining to the use of angiogenesis inhibitors in metastatic colorectal cancer (mCRC). These experts highlight the clinical outcomes of these trial with special attention on trial design and characteristics and eligibility criteria of enrolled subjects. They identify clinical situations in which evidence is robust and others in which more data are needed to better help direct clinical decision making.
0.75 CME

Webcast: IBD Pathogenesis: Personalizing Targets

Recent scientific discoveries regarding the pathobiology of IBD and the number of new and emerging therapies recently approved and in late phase development necessitate education for nurses to enhance their ability to provide personalized care to patients with IBD. This educational activity repeats the session IBD Pathogenesis: Personalizing Targets presented by Laryl Riley, RNP during the satellite symposium Therapeutic Management of IBD: The Paradigm Shift to Personalized Care during the national gastroenterology nursing conference in Baltimore, Maryland, May 16, 2015.
0.5 CNE

Webcast: Personalized Medicine: Right Drug for the Right Patient

Recent scientific discoveries regarding the pathobiology of IBD and the number of new and emerging therapies recently approved and in late phase development necessitate education for nurses to enhance their ability to provide personalized care to patients with IBD. This educational activity repeats the session Personalized Medicine: The Right Drug for the Right Patient presented by Michele Rubin, APN, MSN, CNS, CGRN during the satellite symposium Therapeutic Management of IBD: The Paradigm Shift to Personalized Care during the national gastroenterology nursing conference in Baltimore, Maryland, May 16, 2015.
0.5 CNE

Webcast: Addressing Risks and Benefits of IBD Therapy: The Balancing Act

Recent scientific discoveries regarding the pathobiology of IBD and the number of new and emerging therapies recently approved and in late phase development necessitate education for nurses to enhance their ability to provide personalized care to patients with IBD. This educational activity repeats the session Addressing Risks and Benefits of IBD Therapy: The Balancing Act presented by Maureen Kelly, RN, MS, CPNP during the satellite symposium Therapeutic Management of IBD: The Paradigm Shift to Personalized Care during the national gastroenterology nursing conference in Baltimore, Maryland, May 16, 2015.
0.5 CNE

Webcast: Evolving Paradigms in Castration-Resistant Prostate Cancer: An Online Interactive Opinion Leader Workshop

In the past 4 years, our increased understanding of prostate cancer biology and mechanisms of tumor resistance have led to a number of clinical trials using new therapeutic agents, resulting in several new FDA approvals. Additionally, new agents are currently under clinical investigation in continuous efforts to improve the efficacy and safety of Castration-Resistant Prostate Cancer (CRPC) treatment. The introduction of these novel therapeutic agents, however, requires physicians to make complicated decisions regarding treatment protocols for their patients with CRPC. Questions of agent selection, treatment sequencing methods, combination treatment strategies, and individualized therapeutic approaches for newly approved and emerging CRPC drugs remain unanswered. This activity aims to address these challenges through an interactive online opinion leader workshop with 3 experts in the field of prostate cancer discussing the clinical data regarding available and investigational agents and the most effective ways to utilize those agents for long-term disease control.
1.5 CME

Expert Perspectives: The Clinical Potential of PARP Inhibitors in Ovarian Cancer

In this Expert Perspectives™ activity, Dr. Bradley Monk leads a conversation with Dr. Ursula Matulonis and Dr. Thomas Herzog, on the clinical potential of novel PARP inhibitors for improved management of epithelial ovarian cancer. This discussion is a review of their symposium presented during the 2015 Annual Conference of ASCO.